Menatetrenone for the treatment of osteoporosis

Iwamoto J, Sato Y · Expert Opinion on Pharmacotherapy

RETRACTED, and recorded here so it is not cited again: this review concluded menatetrenone was a reasonable second-line treatment for postmenopausal osteoporosis, and it was retracted by the journal in 2019 (Expert Opin Pharmacother. 2019;20(12):1531). Its co-author's own menatetrenone fracture trials were also retracted.

Population

Systematic review of 13 randomised trials, one meta-analysis and one systematic review of menatetrenone (MK-4) for the skeleton

Intervention

Menatetrenone (MK-4)

Comparator

n/a

Limitations

Retracted publication — it carries no evidential weight and exists in this database only as a marker so the next reader does not re-find and cite it, or the retracted primary trials it summarised.